Skip to main content
Rana McKay, MD, Oncology, La Jolla, CA, UC San Diego Medical Center – Hillcrest

RanaRamziMcKayMD

Oncology La Jolla, CA

Physician

Dr. McKay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. McKay's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2008 - 2011
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 2008

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2016 - 2024
  • MA State Medical License
    MA State Medical License 2011 - 2018
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma  
    Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology

Authored Content

  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020

Press Mentions

  • Combinations Continue to Advance RCC Treatment
    Combinations Continue to Advance RCC TreatmentJanuary 11th, 2018
  • Targeted-Chemo Combination Active in Sarcomatoid, High-Risk RCC
    Targeted-Chemo Combination Active in Sarcomatoid, High-Risk RCCMarch 2nd, 2015
  • Successful ESMO Studies to Likely Trigger Sequencing Shakeup in RCC
    Successful ESMO Studies to Likely Trigger Sequencing Shakeup in RCCSeptember 28th, 2017
  • Join now to see all

Hospital Affiliations